CC BY-NC-ND 4.0 · The Arab Journal of Interventional Radiology 2022; 06(02): 092-098
DOI: 10.1055/s-0042-1757783
Original Article

Endovascular Infusion of Amphotericin B for the Treatment of Rhino-Orbito-Cerebral Mucormycosis: A Pilot Study Assessing Technical Feasibility and Safety

Subhash Kumar
1   Department of Radiodiagnosis, All India Institute of Medical Sciences, Patna, Bihar, India
,
Kranti Bhavana
2   Department of ENT, All India Institute of Medical Sciences, Patna, Bihar, India
,
3   Department of General Medicine, All India Institute of Medical Sciences, Patna, Bihar, India
,
Amarjeet Kumar
4   Department of Anaesthesiology, All India Institute of Medical Sciences, Patna, Bihar, India
,
Mala Mahto
5   Department of Biochemistry, All India Institute of Medical Sciences, Patna, Bihar, India
› Author Affiliations

Abstract

Objectives The aim of this study was to assess the technical feasibility and safety of intra-arterial infusion of amphotericin B for the management of rhino-orbito-cerebral mucormycosis in patients unable to receive full dose and schedule of intravenous amphotericin B and/or unsuitable for surgery.

Materials and Methods Five consecutive patients underwent five sessions of intra-arterial infusion each via both external carotid arteries on alternate days. Liposomal amphotericin B (50 mg) was infused at each session. The baseline and follow-up investigations as well as local and systemic complications were charted.

Results Procedure could be completed for all participants without any local complications. One patient had transient and another had progressive deterioration in renal parameters during the follow-up period of 30 days.

Conclusions Authors conducted successfully a pilot study of multisession intra-arterial infusion of amphotericin B, with the premise that it can provide high concentration of drug at the desired site with reduced systemic complications. They recommend further larger randomized studies to evaluate its efficacy for the management of advanced rhino-oculo-cerebral mucormycosis.

Ethical Statement

The study was conducted after approval of the Institute Ethics Committee, and has therefore been performed in accordance with the ethical standards laid down in the 1964 Helsinki Declaration and its later amendments.




Publication History

Article published online:
01 November 2022

© 2022. The Pan Arab Interventional Radiology Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 
  • References

  • 1 Sen M, Honavar SG, Bansal R. et al; members of the Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC) Study Group. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India - Collaborative OPAI-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol 2021; 69 (07) 1670-1692
  • 2 Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. Indian J Ophthalmol 2021; 69 (04) 1002-1004
  • 3 Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: A systematic review of cases reported worldwide and in India. Diabetes Metab Syndr 2021; 15 (04) 102146
  • 4 Garg D, Muthu V, Sehgal IS. et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. Mycopathologia 2021; 186 (02) 289-298
  • 5 Arora R, Goel R, Khanam S. et al. Rhino-orbito-cerebral-mucormycosis during the COVID-19 second wave in 2021 - a preliminary report from a single hospital. Clin Ophthalmol 2021; 15: 3505-3514
  • 6 Gelston CD, Durairaj VD, Simoes EA. Rhino-orbital mucormycosis causing cavernous sinus and internal carotid thrombosis treated with posaconazole. Arch Ophthalmol 2007; 125 (06) 848-849
  • 7 Honavar SG. Code Mucor: guidelines for the diagnosis, staging and management of rhino-orbito-cerebral mucormycosis in the setting of COVID-19. Indian J Ophthalmol 2021; 69 (06) 1361-1365
  • 8 Cornely OA, Alastruey-Izquierdo A, Arenz D. et al; Mucormycosis ECMM MSG Global Guideline Writing Group. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis 2019; 19 (12) e405-e421
  • 9 Sipsas NV, Gamaletsou MN, Anastasopoulou A, Kontoyiannis DP. Therapy of mucormycosis. J Fungi (Basel) 2018; 4 (03) 90 DOI: 10.3390/jof4030090.
  • 10 De Pauw B, Walsh TJ, Donnelly JP. et al; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group, National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46 (12) 1813-1821
  • 11 Matoba M, Tonami H, Kuginuki M, Yamamoto I, Takashima S. Intermittent hepatic artery antibiotic infusion therapy for pyogenic hepatic abscess. Acta Radiol 2004; 45 (01) 13-17
  • 12 Chujo T, Kuratsune H, Nishimori Y. et al. [Mycotic liver and spleen abscesses successfully treated by intraportal and intrahepatosplenic arterial administration of antimycotic drugs in two cases with acute leukemia]. Rinsho Ketsueki 1989; 30 (05) 736-745 Japanese.
  • 13 Miyata A, Honda K, Fujita M, Kikuchi T. [Multiple candida liver abscesses successfully treated by continuous intrahepatic arterial infusion of amphotericin B using a reservoir in a case with acute myelocytic leukemia (M2)]. Rinsho Ketsueki 1995; 36 (10) 1217-1222
  • 14 Chooklin S, Hranat O, Usach O. Prophylactic of infected pancreatic necrosis by intra-arterial infusion. HPB (Oxford) 2016; 18 (02) e817
  • 15 Suzuki A, Ohtani T, Otani E. [Two cases of intra-arterial infusion of antibiotics in intractable chronic osteomyelitis of the mandible]. Aichi Gakuin Daigaku Shigakkai Shi 1989; 27 (04) 1071-1079
  • 16 Hugeneck J, Gottlob R. [The intra-arterial infusion. II. Its use in the treatment of septic gangrene]. Wien Med Wochenschr 1982; 132 (21) 523-526
  • 17 Mansueto P, Rizzo M, Affronti M. et al. Safe and successful endoarterial infusion of liposomal amphotericin B in treatment of mucormycosis. New Microbiol 2003; 26 (04) 395-398
  • 18 Lentino JR, Pachucki CT, Ramamurthy S, Turner J. Local Arterial Infusion of Amphotericin B for Refractory Aspergillosis. 2002. Accessed September 21, 2022, at: https://www.medscape.com/viewarticle/439192_2
  • 19 Yadav S, Rawal G. Mucormycosis in COVID-19- a burgeoning epidemic in the ongoing pandemic. IP Ind J Immunol Respir Med 2021; 6 (02) 67-70
  • 20 Handzel O, Landau Z, Halperin D. Liposomal amphotericin B treatment for rhinocerebral mucormycosis: how much is enough?. Rhinology 2003; 41 (03) 184-186
  • 21 Stone NR, Bicanic T, Salim R, Hope W. Liposomal amphotericin B (AmBisome(®)): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs 2016; 76 (04) 485-500
  • 22 Sundar S, Jha TK, Thakur CP, Mishra M, Singh VP, Buffels R. Single-dose liposomal amphotericin B in the treatment of visceral leishmaniasis in India: a multicenter study. Clin Infect Dis 2003; 37 (06) 800-804